Lidocaine 2% Fresenius Kabi (Lidocaine Hydrochloride Monohydrate)

Lidocaine works by blocking voltage‑gated sodium channels on nerve membranes, which stops the influx of sodium ions needed for action potential generation. This inhibition prevents nerve impulse propagation, resulting in temporary loss of sensation in the area where it is administered.

The appropriate dose of Lidocaine 2% is determined by the prescribing clinician based on the intended route, procedure, patient weight, age, and comorbidities. Healthcare professionals calculate the amount required to achieve effective anesthesia while staying within safety limits.

Lidocaine is classified as pregnancy category unknown; limited data exist. It should be used during pregnancy or lactation only when the potential benefit justifies any potential risk to the fetus or infant, and under close medical supervision.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lidocaine has a faster onset of action but a shorter duration compared with bupivacaine, which provides longer-lasting analgesia but takes longer to take effect. Choice between them depends on the clinical need for rapid onset versus prolonged block, as well as safety considerations for cardiac toxicity.

Lidocaine 2% solution should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect it from direct sunlight, moisture, and freezing. Inspect the vial for particulate matter before use and discard if the solution appears discolored.

The solution is administered by injection via epidural, intramuscular, or intravenous routes, depending on the clinical indication. Administration techniques follow standard aseptic procedures, and the volume injected is calculated by the prescriber to achieve the desired anesthetic effect.

Serious risks include cardiac arrhythmias, seizures, methemoglobinemia, and severe allergic reactions such as anaphylaxis. Early signs of toxicity—such as tinnitus, metallic taste, or circumoral numbness—should prompt immediate medical evaluation.

Patients with known hypersensitivity to lidocaine or other amide‑type local anesthetics, those with severe heart block, uncontrolled epilepsy, or significant hepatic impairment should avoid its use unless a specialist determines that benefits outweigh risks.